ScreenerHero

BTAI BioXcel Therapeutics, Inc.

Partial data
NAS · US · Healthcare · Biotechnology · bioxceltherapeutics.com
0.0615USD-18.11%Mkt Cap: 2.31M $P/E: —

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immu…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap2.31M USD
Enterprise Value93.02M USD
Revenue (TTM)742.00K USD
Gross Profit478.00K USD
Net Income (TTM)-69.90M USD
Revenue/Share0.03 USD
Last Price0.0615 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees29
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS09075P1057
Valuation
P/E (Trailing)—
P/E (Forward)-0.03
PEG—
EV/EBITDA-2.09
EV/Revenue125.36
P/S3.12
P/B-0.02
EPS (TTM)-2.58
EPS (Forward)-2.14
52W Range
0.01901% of range4.290
52W High4.290 USD
52W Low0.0190 USD
Profitability
Gross Margin74.45%
Oper. Margin-5600.55%
EBITDA Margin0.00%
Profit Margin-10887.38%
ROE73.22%
ROA-155.62%
Growth
Revenue Growth51.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-57.62M USD
CapEx (TTM)—
FCF Margin-4278.37%
FCF Yield-1372.20%
Net Debt91.61M USD
Net Debt/EBITDA-2.06
Balance Sheet
Debt/Equity-1.15
Current Ratio0.21
Quick Ratio0.09
Book Value/Sh-3.69 USD
Cash/Share0.41 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.31.31M
Float26.89M
Insiders0.00%
Institutions4.26%
Technical
SMA 500.0673 (-8.6%)
SMA 2000.0673 (-8.6%)
Beta0.19
S&P 52W Chg13.94%
Avg Vol (30d)11.27M
Avg Vol (10d)548.33K
Technical Indicators
RSI (14)23.2
MACD-0.2308
MACD Signal-0.2149
MACD Hist.-0.0159
BB Upper1.301 USD
BB Middle0.4224 USD
BB Lower-0.4558 USD
BB Width415.86%
ATR (14)0.0820 USD
Vol Ratio (20d)0.02x